Features of systemic therapy for treatment of brain metastases of kidney cancer (literature review)
https://doi.org/10.17650/3034-2473-2025-2-1-44-57
Abstract
The article presents a review of modern methods of systemic therapy in patients with brain metastases of kidney cancer based on analysis of up-to-date literature data which support multimodal treatment strategy including systemic therapy, radiotherapy and/or surgical treatment. The main goal of drug therapy is to slow down metastatic process progression, increase survival of these patients. Currently, the optimal approach to treatment of brain metastases of renal cell carcinoma has not been established.
About the Authors
D. V. Semenov
Saint Petersburg State University ; Saint Petersburg City Clinical Oncological Dispensary
Russian Federation
Russian Federation
Dmitry Vladimirovich Semenov
7–9 Universitetskaya Emb., Saint Petersburg 199034
56 Veteranov Prospekt, Saint Petersburg 198255
R. V. Orlova
Saint Petersburg State University ; Saint Petersburg City Clinical Oncological Dispensary
Russian Federation
Russian Federation
7–9 Universitetskaya Emb., Saint Petersburg 199034
56 Veteranov Prospekt, Saint Petersburg 198255
V. I. Shirokorad
Moscow City Oncological Hospital No. 62, Moscow Healthcare Department
Russian Federation
Russian Federation
27 Istra Village, Moscow Region 143423
S. V. Kostritsky
Moscow City Oncological Hospital No. 62, Moscow Healthcare Department
Russian Federation
Russian Federation
27 Istra Village, Moscow Region 143423
References
1. Achrol A.S., Rennert R.C., Anders C. et al. Brain metastases. Nat Rev Dis Primers 2019;5(1):5. DOI: 10.1038/s41572-018-0055-y
2. Dudani S., de Velasco G., Wells J.C. et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open 2021;4(1):e2021869. DOI: 10.1001/jamanetworkopen.2020.21869
3. Gore M.E., Hariharan S., Porta C. et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011;117(3):501–9. DOI: 10.1002/cncr.25452
4. Daugherty M., Daugherty E., Jacob J. et al. Renal cell carcinoma and brain metastasis: questioning the dogma of role for cytoreductive nephrectomy. Urol Oncol 2019;37(3):182.e9–182.e15. DOI: 10.1016/j.urolonc.2018.10.021
5. Hanzly M., Abbotoy D., Creighton T. et al. Early identification of asymptomatic brain metastases from renal cell carcinoma. Clin Exp Metastasis 2015;32(8):783–8. DOI: 10.1007/s10585-015-9748-8
6. Brown L., Desai K., Wei W. et al. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. J Immunother Cancer 2021;9(9):e003281. DOI: 10.1136/jitc-2021-003281
7. Patchell R.A., Tibbs P.A., Walsh J.W. et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322(8):494–500. DOI: 10.1056/nejm199002223220802
8. Lamba N., Muskens I.S., DiRisio A.C. et al. Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis. Radiat Oncol 2017;12(2):106. DOI: 10.1186/s13014-017-0840-x
9. Yomo S., Oda K., Oguchi K. et al. Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores. J Neurosurg 2022;138(6):1591–9. DOI: 10.3171/2022.9.jns221215
10. Huntoon K., Damante M., Wang J. et al. Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy. Curr Probl Cancer 2022;46(2):100805. DOI: 10.1016/j.currproblcancer.2021.100805
11. Verma J., Jonasch E., Allen P.K. et al. Theimpact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol 2013;36:620–624. DOI: 10.1097/COC.0b013e31825d59db
12. Barata P.C., Mendiratta P., Kotecha R. et al. Effect of switching systemic treatment after stereotactic radiosurgery for oligoprogressive, metastatic renal cell carcinoma. Clin Genitourin Cancer 2018;16(5):413–419.e1. DOI: 10.1016/j.clgc.2018.07.018
13. Kim D.W., Mehra R., Tan D.S.W. et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 2016;17(4):452–63. DOI: 10.1016/S1470-2045(15)00614-2
14. Reungwetwattana T., Nakagawa K., Cho B.C. et al. CNS response to Osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol 2018;36(3):3290–7. DOI: 10.1200/JCO.2018.78.3118
15. Chevreau C., Ravaud A., Escudier B. et al. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer 2014;12(1):50–4. DOI: 10.1016/ j.clgc.2013.09.008
16. Peverelli G., Raimondi A., Ratta R. et al. Cabozantinib in renal cell carcinoma with brain metastases: safety and efficacy in a real-world population. Clin Genitourin Cancer 2019;17(4):291–8. DOI: 10.1016/j.clgc.2019.05.002
17. Hirsch L., Martinez Chanza N., Farah S. et al. Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma. JAMA Oncol 2021;7(12):1815–23. DOI: 10.1001/jamaoncol.2021.4544
18. Cochran D.C., Chan M.D., Aklilu M. et al. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with gamma knife surgery. J Neurosurg 2012;116(5):978–83. DOI: 10.3171/2012.2.JNS111353
19. Khan I.M., Khan S.U., Sala H.S.S. et al. TME-targeted approaches of brain metastases and its clinical therapeutic evidence. Front Immunol 2023;14:1131874. DOI: 10.3389/fimmu.2023.1131874
20. Daneman R., Prat A. The Blood-brain barrier. Cold Spring Harb Perspect Biol 2015;7(1):a020412. DOI: 10.1101/cshperspect.a020412
21. Achar A., Myers R., Ghosh C. Drug delivery challenges in brain disorders across the blood-brain barrier: novel methods and future considerations for improved therapy. Biomedicines 2021;9(12):1834. DOI: 10.3390/biomedicines9121834
22. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312–8. DOI: 10.1200/jco.2008.19.5511
23. Khan M., Zhao Z., Arooj S. et al. Impact of tyrosine kinase inhibitors (TKIs) combined with radiation therapy for the management of brain metastases from renal cell carcinoma. Front Oncol 2020;10:1246. DOI: 10.3389/fonc.2020.01246
24. Dudek A.Z., Raza A., Chi M. et al. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer 2013;11(2):155–60. DOI: 10.1016/j.clgc.2012.11.001
25. Gore M.E., Szczylik C., Porta C. et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 2015;113(1):12–9. DOI: 10.1038/bjc.2015.196
26. Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1814–23. DOI: 10.1056/nejmoa1510016
27. Méndez-Vidal M.J., Molina Á., Anido U. et al. Pazopanib: vidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacol Toxicol 2018;19(1):77. DOI: 10.1186/s40360-018-0264-8
28. Roberto M., Bassanelli M., Iannicelli E. et al. Clinical outcome of third-line pazopanib in a patient with metastatic renal cell carcinoma. Case Rep Oncol Med 2015;2015:629046. DOI: 10.1155/2015/629046
29. Gooch M.E., Nader K., Kubicek G.J., Somer R.A. Brain metastasis responsive to pazopanib in renal cell carcinoma: a case report and review of the literature. Clin Genitourin Cancer 2016;14(4):e401–e4. DOI: 10.1016/j.clgc.2016.01.005.
30. Mojica C.V., Aguas G.V.A., Cornelio G.T.H., Damian L.F. Prolonged survival using first-line pazopanib in a Filipino male with renal cell carcinoma and brain metastasis: a case report. Case Rep Oncol 2021;14(3):1516–21. DOI: 10.1159/000519745
31. Buti S., Bersanelli M., Massari F. et al. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: an Italian case series. World J Clin Oncol 2021;12:1037–46. DOI: 10.5306/wjco.v12.i11.1037
32. Hingorani M., Dixit S., Maraveyas A. Pazopanib-induced regression of brain metastasis after whole brain palliative radiotherapy in metastatic renal cell cancer progressing on first-line sunitinib: a case report. World J Oncol 2014;5(5–6):223–7. DOI: 10.14740/wjon843w
33. Albiges L., Tannir N.M., Burotto M. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5(6):e001079. DOI: 10.1136/esmoopen-2020-001079
34. Tykodi S.S., Gordan L.N., Alter R.S. et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer 2022;10(2):e003844. DOI: 10.1136/jitc-2021-003844
35. Emamekhoo H., Olsen M., Carthon B.C. et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer 2021;128(5):966–74. DOI: 10.1002/cncr.34016
36. Flippot R., Dalban C., Laguerre B. et al. Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. J Clin Oncol 2019;37(23):2008–16. DOI: 10.1200/JCO.18.02218
37. Courcier J., Dalban C., Laguerre B. et al. Primary renal tumour response in patients treated with nivolumab for metastatic renal cell carcinoma: results from the GETUG-AFU 26 NIVOREN trial. Eur Urol 2021;80(3):325–9. DOI: 10.1016/j.eururo.2021.05.020
38. Choueiri T.K., Motzer R.J., Rini B.I. et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020;31(8):1030–9. DOI: 10.1016/j.annonc.2020.04.010
39. Jonasch E., Hasanov E., Hariharan S. et al. Evaluation of brain metastasis in JAVELIN Renal 101: efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S). J Clin Oncol 2020;38(6 suppl):687. DOI: 10.1200/jco.2020.38.6_suppl.687
40. Baston C., Parosanu A., Stanciu I.M., Nitipir C. Metastatic kidney cancer: does the location of the metastases matter? Moving towards personalized therapy for metastatic renal cell carcinoma. Biomedicines 2024;12(5):1111. DOI: 10.3390/biomedicines12051111
41. Hasanov E., Yeboa D., Tucker M.D. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin 2022;72(5):454–89. DOI: 10.3322/caac.21729
Review
For citations:
Semenov D.V., Orlova R.V., Shirokorad V.I., Kostritsky S.V. Features of systemic therapy for treatment of brain metastases of kidney cancer (literature review). Supportive Therapy in Oncology. 2025;2(1):44-57. (In Russ.) https://doi.org/10.17650/3034-2473-2025-2-1-44-57
Views:
77
Email this article 